| 生物活性 |
SNX-7081 is an Hsp90 inhibitor with Ki and IC50 values of 26 and 44 nM, respectively, that blocks NF-κB nuclear translocation, suppresses pro-inflammatory cytokine production, downregulates ERK/JNK and PDGF signaling pathways, and inhibits LPS (MS-X54539)-induced nitric oxide production; moreover, it inhibits DNA repair, induces G2/M cell cycle arrest, and triggers apoptosis (apoptosis) through MYC/nucleolin downregulation and Fas activation, making it useful for research on rheumatoid arthritis and cancer. |
体外研究 (In Vitro) |
SNX-7081 (0.0001-10 μM; 6-24 h) 可抑制 NF-κB 的核转位,在 IL-1β 刺激的人脐静脉内皮细胞中其 IC50 值为 114 nM,在 LPS 刺激的 J774 小鼠巨噬细胞中为 241 nM,在 IL-1β 刺激的类风湿关节炎滑膜成纤维细胞中为 44 nM,在 TNF-α 刺激的类风湿关节炎滑膜成纤维细胞中为 88 nM。 SNX-7081 (6-24 h) 可强效抑制 THP-1 人单核细胞、人脐静脉内皮细胞及类风湿关节炎滑膜成纤维细胞中多种促炎细胞因子的产生,其 IC50 值低至 13 nM;同时可抑制活化的人脐静脉内皮细胞增殖,IC50 为 3 nM,而对类风湿关节炎滑膜成纤维细胞的增殖影响极小。 SNX-7081 (0.001-10 μM; 24 h) 可抑制人脐静脉内皮细胞中生长因子诱导的 ERK-1/2 信号通路,其 IC50 为 11 nM;抑制人脐静脉内皮细胞中 IL-1β 诱导的 JNK 信号通路,IC50 为 94 nM;抑制 NIH3T3 小鼠成纤维细胞中 PDGF 诱导的整体酪氨酸信号通路,IC50 为 56 nM;还可抑制 NIH3T3 小鼠成纤维细胞中 PDGF 诱导的 ERK-1/2 信号通路,IC50 为 14 nM。 SNX-7081 (0.001-10 μM; 6 h) 可抑制 LPS 诱导的 J774 小鼠巨噬细胞中一氧化氮的产生,其 IC50 为 6 nM。 SNX-7081 (100 nM; 48 h) 可在 MEC1 细胞中引发广泛的蛋白表达变化,包括 DNA 复制与修复蛋白的显著下调,以及能量代谢和蛋白质代谢相关蛋白的表达上调。 SNX-7081 (100 nM; 48 h) 可改变 MEC1 细胞中关键调控蛋白的水平,包括 NFκB2 p52、MYC 和 BRCA1 的表达降低。 SNX-7081 (100 nM; 48 h) 可在 p53 突变型 MEC1、MEC2 和 U266 B 淋巴癌细胞中诱导 DNA 损伤标志物 γH2AX 发生轻微升高。 SNX-7081 (100 nM; 48 h) 可在 MEC1 细胞中引发广泛的蛋白表达变化,包括 DNA 损伤、表观遗传调控和促凋亡相关蛋白的表达上调,以及 DNA 复制和修复相关蛋白的表达下调。 SNX-7081 (100 nM; 48 h) 可改变 MEC1 细胞中关键调控蛋白的水平,包括 MYC、CCND1 和 BRCA1 的表达量降低。 SNX-7081 (100 nM; 48 h) 可在携带 p53 突变的 MEC1、MEC2 和 U266 B 淋巴细胞癌细胞中协同提升 DNA 损伤标志物 γH2AX 的表达水平。 SNX-7081 (72 h) 可强效抑制 K562、A375、MCF-7、Hep-2、HepG2、A549、SW-620 及 HeLa 人源癌细胞的生长,平均 IC50 约为 1 μM,同时对 L-02、HDF 及 MRC5 人源正常细胞的细胞毒性较低。 SNX-7081 (1 μM; 48 h) 可在 K562、Hep-2、A549、SW-620 和 HeLa 人癌细胞中诱导 G2/M 期细胞周期阻滞,且相较于 SNX-2112,其在 K562、Hep-2 和 A549 细胞中的活性更强。 SNX-7081 (1 μM; 48 h) 可在 K562、A375、Hep-2、A549、SW-620 和 HeLa 人癌细胞中诱导细胞凋亡,且其对 K562、Hep-2 和 A549 细胞的活性相较于 SNX-2112 更强。 SNX-7081 (1 μM; 0-48 h) 以时间依赖的方式降低人白血病细胞 K562 中 Hsp90 客户蛋白 IKKα、CHK1、GSK3 和 Raf-1 的表达,其效力强于 SNX-2112。
Western Blot Analysis
| Cell Line: |
human p53-negative MEC1 chronic lymphocytic leukemia cells |
| Concentration: |
100 nM |
| Incubation Time: |
48 h |
| Result: |
Significantly decreased NFκB2 p52 levels. Significantly decreased MYC levels. Significantly decreased BRCA1 levels. Induced a non-significant increase in cyclin D1 (CCND1) levels. |
Western Blot Analysis
| Cell Line: |
human p53-negative MEC1 chronic lymphocytic leukemia cells |
| Concentration: |
100 nM (combined with 10 μM 2-FaraA) |
| Incubation Time: |
48 h |
| Result: |
Significantly decreased MYC levels. Significantly decreased CCND1 levels. Significantly decreased BRCA1 levels. |
Cell Cycle Analysis
| Cell Line: |
K562, Hep-2, A549, SW-620, HeLa |
| Concentration: |
1 μM |
| Incubation Time: |
48 h |
| Result: |
Induced G2/M phase cell cycle arrest in all tested cancer cell lines. Increased the percentage of cells in G2/M phase to 22.6% (K562), 35.0% (Hep-2), 13.6% (A549), 27.0% (SW-620), and 17.6% (HeLa), compared to control levels of 3.1% (K562), 6.8% (Hep-2), 4.3% (A549), 7.4% (SW-620), and 10.7% (HeLa). Was more effective at inducing G2/M arrest than SNX-2112 in K562, Hep-2, and A549 cells, but less effective in SW-620 and HeLa cells. |
Apoptosis Analysis
| Cell Line: |
K562, A375, Hep-2, A549, SW-620, HeLa |
| Concentration: |
1 μM |
| Incubation Time: |
48 h |
| Result: |
Induced apoptosis in all 6 tested cancer cell lines. Increased the percentage of apoptotic cells to 22.3% (K562), 48.7% (A375), 17.9% (Hep-2), 33.2% (A549), 16.7% (SW-620), and 13.8% (HeLa), compared to control levels of 4.0% (K562), 5.5% (A375), 7.5% (Hep-2), 11.8% (A549), 6.5% (SW-620), and 5.6% (HeLa). Induced more apoptosis than SNX-2112 in K562, Hep-2, and A549 cells, but less apoptosis in SW-620 and HeLa cells. |
Western Blot Analysis
| Cell Line: |
K562 |
| Concentration: |
1 μM |
| Incubation Time: |
0, 6, 12, 24, 48 h |
| Result: |
Reduced the expression of Hsp90 client proteins (IKKα, CHK1, GSK3, Raf-1) in a time-dependent manner. Decreased protein levels to 11.7% (IKKα), 21.8% (CHK1), 5.8% (GSK3), and 10.4% (Raf-1) of control levels after 48 h of treatment. Exerted stronger inhibitory effects on these client proteins than SNX-2112. |
|